Is Kymera Therapeutics, Inc. (KYMR) a Buy, Sell, or Hold?
NASDAQ : KYMR
Kymera Therapeutics, Inc.
$114.12 USD
$2.04 (1.82%)
- Volume
- 411.01K
- Average Volume
- 794.36K
- Market Capitalization
- $9.39B
- P/E Ratio
- -31.88
- Dividend Yield
- 0.00%
- Price Target
- $129.00
- Year High
- $130.05
- Year Low
- $36.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.81
Analyst Rating
Strong Sell
1 Rating Score
UPSIDE/DOWNSIDE
-11.5% DOWNSIDE
$129.00 Price Target
UPSIDE/DOWNSIDE HIGH
-26.4% DOWNSIDE
$155.00 Price Target High
UPSIDE/DOWNSIDE LOW
17.6% UPSIDE
$97.00 Price Target Low
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| RBC Capital | Brian Abrahams | $115 | $119.35 | 2026-07-13 06:34 AM | -3.6% |
| Truist Financial | Srikripa Devarakonda | $136 | $108.12 | 2026-06-29 07:22 AM | 25.8% |
| Canaccord Genuity | Edward Nash | $129 | $116.46 | 2026-06-26 07:55 AM | 10.8% |
| B.Riley Financial | Kalpit Patel | $155 | $116.46 | 2026-06-26 06:57 AM | 33.1% |
| Loop Capital Markets | Leah Rush Cann | $97 | $73.95 | 2026-06-08 01:05 PM | 31.2% |
| Canaccord Genuity | Edward Nash | $106 | $82.71 | 2026-05-06 05:22 AM | 28.2% |
| Morgan Stanley | Judah Frommer | $119 | $80.73 | 2026-04-30 11:56 AM | 47.4% |
| Morgan Stanley | Judah Frommer | $123 | $95.03 | 2026-02-26 03:25 PM | 29.4% |
| RBC Capital | Brian Abrahams | $108 | $91.8657 | 2026-02-26 11:56 AM | 17.6% |
| Barclays | Eliana Merle | $133 | $72.15 | 2026-01-27 04:26 PM | 84.3% |